MedTrace Logo

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

NCT03870776 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-03-31

No results posted yet for this study

Summary

The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.

Conditions

Interventions

DRUG

MAP4343

Daily oral administration of MAP4343

DRUG

Placebo

Daily oral administration of Placebo

Sponsors & Collaborators

  • Eurofins Optimed

    collaborator INDUSTRY

  • Mapreg

    lead INDUSTRY

Principal Investigators

  • Isabelle VILLEY, PhD, MBA · Mapreg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2024-11-07
Completion
2024-11-07

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03870776 on ClinicalTrials.gov